Adma Biologics, Inc. ADMA
We take great care to ensure that the data presented and summarized in this overview for ADMA BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADMA
View all-
Black Rock Inc. New York, NY18.6MShares$295 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$288 Million0.01% of portfolio
-
State Street Corp Boston, MA14.9MShares$236 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA11.3MShares$179 Million0.04% of portfolio
-
Morgan Stanley New York, NY5.53MShares$87.7 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA5.43MShares$86 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.67MShares$73.9 Million0.02% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL4.55MShares$72.1 Million0.02% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M3.88MShares$61.4 Million0.03% of portfolio
-
American Century Companies Inc Kansas City, MO3.77MShares$59.8 Million0.04% of portfolio
Latest Institutional Activity in ADMA
Top Purchases
Top Sells
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Transactions at ADMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Alison Cecily Finger |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+23.77%
|
-
|
|
Feb 19
2025
|
Jerrold B Grossman |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+2.23%
|
-
|
|
Feb 19
2025
|
Steve Elms |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+11.09%
|
-
|
|
Feb 19
2025
|
Lawrence P. Guiheen |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+6.2%
|
-
|
|
Feb 19
2025
|
Eduardo Rene Salas |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+50.0%
|
-
|
|
Feb 19
2025
|
Young Kwon |
SELL
Grant, award, or other acquisition
|
Direct |
10,889
-4.14%
|
-
|
|
Feb 19
2025
|
Adam S Grossman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
252,022
+10.17%
|
-
|
|
Feb 19
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
BUY
Grant, award, or other acquisition
|
Direct |
77,784
+12.93%
|
-
|
|
Feb 19
2025
|
Brad L. Tade CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
62,227
+19.21%
|
-
|
|
Jan 30
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
3,355
-0.75%
|
$53,680
$16.1 P/Share
|
|
Jan 30
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.1%
|
$50,000
$10.8 P/Share
|
|
Dec 31
2024
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,343
-0.72%
|
$243,831
$17.15 P/Share
|
|
Dec 31
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
1,854
-0.42%
|
$31,518
$17.15 P/Share
|
|
Nov 27
2024
|
Steve Elms |
BUY
Exercise of conversion of derivative security
|
Indirect |
9,000
+0.42%
|
$90,000
$10.8 P/Share
|
|
Nov 22
2024
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
48,967
-2.4%
|
$1,028,307
$21.1 P/Share
|
|
Nov 22
2024
|
Brad L. Tade CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
15,000
-7.0%
|
$315,000
$21.15 P/Share
|
|
Sep 30
2024
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,752
-1.06%
|
$413,288
$19.99 P/Share
|
|
Sep 30
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
2,647
-0.59%
|
$50,293
$19.99 P/Share
|
|
Sep 09
2024
|
Lawrence P. Guiheen |
SELL
Open market or private sale
|
Direct |
9,000
-5.52%
|
$162,000
$18.47 P/Share
|
|
Sep 09
2024
|
Lawrence P. Guiheen |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+5.23%
|
$90,000
$10.8 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.41M shares |
|---|---|
| Exercise of conversion of derivative security | 810K shares |
| Open market or private sale | 2.52M shares |
|---|---|
| Payment of exercise price or tax liability | 257K shares |
| Bona fide gift | 10K shares |
| Other acquisition or disposition | 460K shares |
| Grant, award, or other acquisition | 10.9K shares |